Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerElise A. Olsen, Eric C. Vonderheid, Sean Whittaker et al.|Journal of Clinical Oncology|2011Cited by 657
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Brigitte Dréno et al.|The Lancet|2017Cited by 580
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017Franz Trautinger, Robert Knobler, Johanna Eder et al.|European Journal of Cancer|2017Cited by 449
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic ModelJulia Scarisbrick, Henry K. Wong, H. Miles Prince et al.|Journal of Clinical Oncology|2015Cited by 419
The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patientsJulia Scarisbrick, Andrew Bates, Pietro Quaglino et al.|British Journal of Dermatology|2018Cited by 235